Pneumocystis jirovecii Pneumonia during Brentuximab Vedotin Therapy: A Case Report and Literature Review

Brentuximab vedotin (BV), an antibody drug conjugate against CD30, has been increasingly used in clinical practice, and the less common adverse events associated to the drug are not well described. Also, opportunistic infections have been reported, and data on immune reconstitution after use of BV a...

Descripción completa

Detalles Bibliográficos
Autores principales: Ferreira, Aliana Meneses, Ramos, Jessica Fernandes, Fatobene, Giancarlo, Rocha, Vanderson
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2019
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6458937/
https://www.ncbi.nlm.nih.gov/pubmed/31049233
http://dx.doi.org/10.1155/2019/8982937

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6458937/
https://www.ncbi.nlm.nih.gov/pubmed/31049233
http://dx.doi.org/10.1155/2019/8982937

Ejemplares similares